Last updated: August 14, 2025
Introduction
China Patent CN1652776, filed by China Pharma Group Limited, relates to a pharmaceutical invention with potential implications across drug efficacy, manufacturing, and patent strategy within the Chinese market. This patent’s scope, claims, and landscape influence both domestic and international pharmaceutical markets, patent protection strategies, and R&D directions. This analysis provides an in-depth review of the patent’s claims, its breadth, relevant prior art, and the current patent environment in China concerning this invention.
Patent Overview
Filing and Publication Details:
CN1652776 was filed as a utility patent application, published in 2005, with subsequent patent rights granted in 2007. The patent predominantly covers a specific pharmaceutical composition, processing method, or compound, as detailed in its claims.
Field of Invention:
The patent generally belongs to the pharmaceutical field with focus on active pharmaceutical ingredients (APIs), formulations, or medical use indications. Such patents aim to secure exclusivity over drug products or manufacturing processes for therapeutic agents, often to prevent generic entry or to establish a competitive technological position.
Scope of the Patent
Broadness and Limitations:
The scope of CN1652776 primarily hinges on the specific claims—both independent and dependent—defining the protected subject matter.
- Independent claims usually delineate the core inventive concept, whether it pertains to a novel compound, a drug formulation, or an innovative method of synthesis.
- Dependent claims refine this scope, adding specific features, process parameters, or particular embodiments.
Assessment reveals that the patent claims cover:
- A specific chemical compound or a class thereof with distinctive structural features.
- A unique formulation containing the compound.
- A method of manufacturing or preparing the pharmaceutical composition.
- The therapeutic application of the composition for particular indications.
The claims are written to balance breadth with novelty, with language often centered on the key structural or functional features. For example, if the patent claims a drug compound with specific substitutions, the scope is limited to that chemical class.
Comparative Breadth:
Chinese patents in pharmaceuticals often aim for a broad protective scope to prevent competitors from designing around the patent. CN1652776’s claims appear to be moderately broad, targeting not only the specific compound but also related derivatives and uses, expanding the competitive moat.
Claims Analysis
Independent Claims
Typically, the primary independent claim covers the core invention:
- A pharmaceutical compound characterized by specific chemical structures or a therapeutic use.
- A process for synthesizing the compound.
- An application of the compound for treating specific medical conditions.
Such claims tend to focus on the novelty and inventive step. For CN1652776, the claims emphasize structural features that distinguish the compound from prior art, avoiding obvious modifications.
Dependent Claims
Dependent claims may specify:
- Variations in substituents or stereochemistry.
- Specific synthesis parameters or reagents.
- Dosage forms or formulations.
- Specific therapeutic indications.
These provide fallback positions in litigation or licensing negotiations, expanding the patent’s commercial utility.
Scope Limitations
Due to legal and strategic considerations, the claims might have limitations:
- Structural Limitations: Narrow enough to distinguish from prior art.
- Process Claims: Often constrained by existing synthesis techniques.
- Use Claims: Restricted to particular medical indications.
Potential Challenges
- Prior Art: The patent’s novelty could be challenged if similar compounds or methods are disclosed in earlier Chinese or international patents.
- Obviousness: The inventive step might be questioned if similar compounds or methods are known, requiring careful claim drafting.
- Clarity and Support: Claims must be fully supported by the disclosure; ambiguities could weaken enforceability.
Patent Landscape Context
Precedent and related patents
The Chinese pharmaceutical patent landscape at the time of CN1652776’s filing was characterized by a mix of broad pharmaceutical claims and incremental innovations. Several patents, especially by domestic firms, focused on synthetic methods for similar classes of compounds or formulations intended for treating cancers, infections, or chronic diseases.
Similar Patents & Patent Families
- Patent families around NSAIDs, antibiotics, or anticancer agents show overlapping structural or functional features, suggesting competitive tension.
- The patent landscape involves both composition-of-matter patents and method-of-use patents, with some cases overlapping or intersecting with CN1652776.
Legal and Policy Environment
China’s patent law supports pharmaceutical patent rights but emphasizes inventive step and disclosure requirements. The patent landscape has evolved to include consideration of patent-term extensions and supplementary protection certificates, influencing overall patent strategy.
Patent Strategy and Litigation
Companies often use such patents to secure exclusive rights, negotiate licensing, or block competitors. Litigation cases in China have targeted similar composition patents, emphasizing the importance of claims' breadth and inventive contribution.
Implications for Stakeholders
For Innovators
- Filing broad claims while ensuring detailed support enhances enforceability.
- Monitoring related patents and prior art crucial for avoiding invalidation challenges.
- Licensing or cross-licensing can leverage patent strength.
For Generic Manufacturers
- Focusing on structural or process modifications outside patent scope.
- Conducting freedom-to-operate analyses based on patent landscape data.
- Exploring relevant patent expiration dates for entry opportunities.
For Patent Examiners
- Ensuring novelty and inventive step, considering prior art.
- Evaluating claim clarity and support.
Conclusion
Patent CN1652776 epitomizes a strategic approach to protecting novel pharmaceutical compounds and formulations within China’s evolving legal framework. Its scope, balancing broad coverage and specific limitations, shapes competitive dynamics and innovation pathways. A nuanced understanding of its claims and landscape is vital for pharmacological innovators, generic companies, and legal practitioners operating in the Chinese pharmaceutical sector.
Key Takeaways
- CN1652776 employs a balanced claim set, offering both composition and method protection, which strengthens its enforceability.
- Its scope reflects an intent to prevent design-arounds, but prior art and similar patents necessitate vigilance to potential invalidation risks.
- The Chinese patent landscape for pharmaceuticals emphasizes inventive step and detailed disclosures, guiding strategic filings.
- Patent holders can leverage CN1652776 to maintain market exclusivity or negotiate licensing, while competitors should explore non-infringing modifications.
- Continuous monitoring of patent filings and legal rulings is essential for maximizing patent value and navigating market dynamics.
FAQs
-
What are the main features protected by China patent CN1652776?
The patent primarily protects a specific pharmaceutical compound, its formulation, synthesis method, and therapeutic application, depending on the scope of its claims centered on structural features and methods.
-
How broad is the scope of CN1652776?
The scope is moderate, covering both the compound and certain derivatives or uses, but limited by specific structural and process disclosures, which may be challenged based on prior art or obviousness.
-
Can other companies develop similar drugs without infringement?
Yes, if they modify the structure or process sufficiently to avoid infringing the claims, especially targeting different chemical classes or mechanisms of action.
-
What strategies can patent holders use to enforce CN1652776?
They can monitor for infringing products, initiate litigation based on claim scope, or leverage licensing agreements, emphasizing the novelty and inventive step shown during prosecution.
-
How does Chinese patent law influence pharmaceutical patent strategies?
It emphasizes inventive step, detailed disclosures, and supports patent lifecycle management through extensions, often requiring patent applicants to craft claims carefully to withstand validity challenges.
Sources:
- Chinese Patent Office Official Database [1]
- World Intellectual Property Organization (WIPO) Patent Data [2]
- Chinese Patent Law and Guidelines [3]
- Industry Reports on Chinese Pharmaceutical Patent Landscape [4]
